I have been working in the field of molecular medicine (cancer, complement system and blood coagulation disorders), structural bioinformatics and chemoinformatics for over 20 years in different countries (mainly USA, Finland, Sweden, France), in the private and academic sectors. Presently I focus on challenging targets including protein-membrane interactions (e.g., coagulation factor V and factor VIII), protein-protein interactions (eg., VEGFR, Bcl, SYK... see also CDithem), prediction of some ADME-Tox properties and the rational optimization of small molecules (hit2lead).

I am research director at the Inserm Institute (the French National Institute of Health and Medical Research is a public scientific and technological institute which operates under the joint authority of the French Ministry of Health and French Ministry of Research) and head of the research unit U973, this unit is located on the University Paris Diderot campus. I have been codirector of the doctoral school MTCI from 2012-2015, in the scientific committee of the Aviesan National Institute TS from June 2015-June 2016 but this is no longer the case as I have presently a different vision of how research in this area should run at the French national level...


Some more info
Summary of discussions between Dr. B. Villoutreix and several journalists, in 2014, 2015 for the French Inserm Journal Science & Santé and for the movie Rêves de recherche, rêve de chercheur, end of 2010. The discussions were about my previous works (like around the years 2000-2005) and how these studies were contributing to molecular medicine, and how these relate to my present research projects.

Examples of contributions combining in silico and experimental approaches in the field of cancer and coagulation-complement and how these relate to my present research projects
-Around 1994: analysis of protein-protein interfaces in blood coagulation and the complement system and the inhibition of these interactions with antibodies and peptides (USA)
-Around 1994: the use of structural bioinformatics to study therapeutic targets, like the prostate specific antigen (PSA, first structural model) and the use of protein-protein docking to help the design of antibodies to measure PSA free and PSA in complex with serpin molecules (USA, Sweden, Finland). Then, many other proteins important for human health were investigated, like proteins involved in the anticoagulant protein C pathway
-Around 1994: the use of structural analysis to investigate point mutations identified in patients, essentially for thrombosis and bleeding disorders (USA)
-Around 1995: modulation of proteins with heparin
-Around 1995: the use of ligand docking tools while working in the private sector (Biotech in Finland)
-Around 1998: the first structural model of a discoidin domain (Sweden)
-Around 2003: stabilization of proteins via site directed mutagenesis designed after computational analysis, area of hemophilia, for a big pharma in the USA
-Around 2003: virtual screening and more specifically hierarchical virtual screening (France), applications in cancer, coagulation, ...
-Around 2005-2006: computer design of low molecular weight compounds that mimic a protein-protein interaction and the design of a molecule that is now in clinical trial phase 1b (Sweden)
-Around 2006: tools to compute some ADMET properties (France)
-Around 2006: modulation of protein-membrane interactions (France)

My work is now on combining bioinformatics and chemoinformatics with experimental studies to design chemical probes, hit candidates and optimized compounds for drug discovery projects, the main therapeutic areas are coagulation-complement and cancer. The intention is to study challenging targets and mechanisms, such as protein-protein interactions or protein-membrane interactions, or some other novel targets, searching for new ideas and solutions that could help patients.